Posaconazole: A new broad-spectrum antifungal agent

Douglas S. Kwon, Eleftherios Mylonakis

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical efficacy in the treatment of oropharyngeal candidiasis and has shown promise as salvage therapy for invasive aspergillosis, zygomycosis, cryptococcal meningitis and a variety of other fungal infections. In addition, data from randomized controlled studies support its efficacy for use in prophylaxis of invasive fungal infections in patients who are severely immunocompromised. The wide spectrum activity of posaconazole in in vitro studies, animal models and preliminary clinical studies suggest that posaconazole represents an important addition to the antifungal armamentarium.

Original languageEnglish (US)
Pages (from-to)1167-1178
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number8
StatePublished - Jun 2007


  • Aspergillosis
  • Aspergillus spp.
  • Candida spp.
  • Candidiasis
  • Coccidiodomycosis
  • Cryptococcal meningitis
  • Fusariosis
  • Histoplasmosis
  • Posaconazole
  • Scedosporiasis
  • SCH-56592
  • Zygomycosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Posaconazole: A new broad-spectrum antifungal agent'. Together they form a unique fingerprint.

Cite this